Skip to main content

Table 8 Distribution and clinical characteristcs of the COEUR cases per Canadian province

From: Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers

  Location of tumor bank Quebec Ontario Manitoba Alberta British Columbia Total
Total cases 976 330 242 17 479 2046
Histotype BOT 9 4 7 0 3 23
HGSC 603 199 120 10 314 1246
EC 132 56 31 3 73 295
LGSC 52 24 19 0 8 103
CCC 123 37 36 1 62 259
MC 43 1 28 2 14 88
other 14 8 1 1 4 29
Age (mean years)a at diagnosis 63 60 61 61 62 62
at end of follow-up 66 64 65 66 66 65
Year of diagnosis (range)   1992–2015 1996–2013 2012–2015 1998–2015 1998–2013 1992–2015
Follow-up (mean, months)   54(0–270) 51(0–168) 32(9–49) 49(0–181) 47(0–173) 48(0–270)
Survival ratea Disease specific survival 30% 41% 73% 36% 29% 33%
5-years survival rate 31% 40% NA 42% 33% 34%
Long Term Survival rate [> 10 years] 9% 7% NA 12% 6% 8%
Treatment type none 47 5 55 0 23 130
carboplatin+taxol 690 238 160 15 351 1454
cisplatin+taxol 40 28 9 0 20 97
platinum 21 21 15 0 45 102
platinum+other 47 2 1 0 6 56
taxol 3 0 0 0 0 3
other 15 6 0 0 1 22
Total 863 300 240 15 446 1864
% response to treatmenta 69% 84% 90% 91% 71% 75%
BRCA mutation carrier status non carriers 306 27 6 9 137 485
carriers 58 16 2 4 33 113
total 370 33 8 13 170 594
% carriers 16% 48% 25% 31% 19% 19%
  1. NA non applicable, BOT borderline tumor, HGSC High-Grade Serous Carcinoma, EC Endometrioid Carcinoma, LGSC Low-Grade Serous Carcinoma, CCC Clear Cell Carcinoma, MC Mucinous Carcinoma
  2. a HGSC patients only